All 11 patients had received systemic therapy for lung cancer before the diagnosis of LM with bloomy rind sign: 9 with an EGFR-TKI, one with an EGFR-TKI plus an anti-angiogenic antibody, and another with cytotoxic anti-cancer drugs plus an anti-angiogenic antibody (Table 1). This evidence concerns the gene EGFR and lung cancer.